Three case reports in patients with synchronous prostate cancer and colorectal, gastric, or pancreatic cancer suggested the feasibility of PSMA-targeted PET/CT for detection of the primary tumor and/or its metastases [10,13,14,15]. This evidence concerns the gene FOLH1 and prostate cancer.